Endocrine gland neoplasm
MONDO:0002082A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.
Also known as: endocrine gland neoplasm (disease), endocrine gland tumor, endocrine gland tumour, endocrine neoplasm, endocrine system neoplasm, endocrine system tumor, endocrine system tumour, endocrine tumor
4375 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 700 trials in this tab.
-
Can a cancer vaccine train the body to fight advanced tumors?
⭐️ CURE ⭐️ CompletedThis phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…
Phase: PHASE1 • Sponsor: Aston Sci. Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Triple immunotherapy cocktail shows promise in tough cancers
Disease control CompletedThis study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Can math make thyroid hormone therapy more precise?
Disease control CompletedThis trial tests a new way to personalize the dose of levothyroxine, a thyroid hormone medication, for people who have had surgery for thyroid cancer. Using mathematical and statistical models, the approach aims to predict the best dose for each individual, potentially reducing s…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental drug combo takes on tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cocktail of drugs aims to tackle tough lung cancer
Disease control CompletedThis phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a glowing dye help surgeons remove pituitary tumors more completely?
Disease control CompletedThis trial tests whether giving a fluorescent dye called indocyanine green during endoscopic surgery helps surgeons remove non-functioning pituitary macroadenomas more completely. About 34 adults with these tumors will be randomly assigned to receive the dye or not during surgery…
Phase: NA • Sponsor: Tomislav Felbabić • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Targeted drug regorafenib tested in rare thyroid cancer
Disease control CompletedThis phase II study tests the targeted therapy regorafenib (Stivarga) in 8 people with metastatic medullary thyroid cancer that has progressed after prior treatment. The drug aims to block cancer growth by targeting specific proteins. Researchers are measuring how long participan…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
Disease control CompletedThis phase II trial is testing an oral drug called RAD001 (everolimus) in people with advanced thyroid cancer that no longer responds to radioactive iodine treatment. The drug works by blocking a key growth pathway (mTOR) in cancer cells. The study aims to see if RAD001 can slow …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New radiation beads take on standard chemo for liver cancer
Disease control CompletedThis study compares a new treatment called TheraSphere (tiny radioactive beads) to standard chemoembolization for people with liver cancer that cannot be removed by surgery. About 92 Chinese adults with early-to-mid stage liver cancer will be randomly assigned to one of the two t…
Phase: PHASE3 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo takes on Hard-to-Treat cancers in first human test
Disease control CompletedThis early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Immune booster after CAR-T shows promise in early lymphoma trial
Disease control CompletedThis early-phase study tested an experimental drug called NT-I7 (efineptakin alfa) in 17 people with relapsed or refractory large B-cell lymphoma who had already received CAR-T cell therapy. The goal was to see if giving NT-I7 after CAR-T is safe and tolerable, and to look for ea…
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for tough lung cancer: LAGOON trial tests powerful drug combo
Disease control CompletedThis study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new op…
Phase: PHASE3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a cancer drug stop liver tumors from returning after ablation?
Disease control CompletedThis study is testing whether giving a PD-1 inhibitor (a type of immunotherapy) after microwave ablation can help prevent early-stage liver cancer from coming back. About 200 adults with early liver cancer will receive the drug every three weeks for nine cycles. The main goal is …
Phase: NA • Sponsor: Chen Xiaoping • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a black seed extract boost immunotherapy against a rare cancer?
Disease control CompletedThis pilot trial is testing whether adding NP-101, a compound from black seed oil, to two immunotherapy drugs (nivolumab and ipilimumab) can help control advanced or metastatic extra-pulmonary neuroendocrine carcinoma (EP-NECA) that has progressed after initial treatment. About 1…
Phase: PHASE1 • Sponsor: Amr Mohamed MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…
Phase: PHASE1, PHASE2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase: PHASE1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a simple belly press make liver cancer radiation more precise?
Disease control CompletedThis trial is testing a new abdominal compression technique to reduce breathing-related movement of liver tumors during radiation therapy. The study will compare this novel method with current compression devices and traditional thermoplastic masks in 120 adults receiving radiati…
Sponsor: Southern Medical University, China • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immune drug plus targeted chemo shows promise for liver cancer in early trial
Disease control CompletedThis early-phase study tests whether combining the immune-boosting drug nivolumab with a procedure that delivers chemotherapy directly to liver tumors (called deb-TACE) is safe for people with advanced liver cancer. Twenty participants will receive the combination, and researcher…
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase: PHASE1, PHASE2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug SKB410 enters human testing for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a One-Two punch of heat and drainage tame inoperable bile duct cancer?
Disease control CompletedThis trial is testing a personalized treatment for people with inoperable perihilar cholangiocarcinoma, a type of bile duct cancer. The approach combines radiofrequency ablation — using heat to destroy tumor tissue — with complete drainage of bile ducts, guided by both endoscopy …
Phase: NA • Sponsor: Clinical Hospital Colentina • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an RNAi drug shrink Hard-to-Treat tumors?
Disease control CompletedThis phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…
Phase: PHASE1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
A drug used during liver surgery may cut the risk of major complications — a study puts it to the test
Disease control CompletedThis study looks at whether giving a drug called terlipressin continuously during keyhole (laparoscopic) liver surgery can lower the chance of severe complications afterward. Terlipressin helps keep blood pressure stable, which may protect organs during surgery. Researchers will …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can High-Dose vitamin c boost chemo against pancreatic cancer?
Disease control CompletedThis phase II trial tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with metastatic pancreatic cancer live longer. About 40 participants are randomly assigned to receive either standard chemo alone or …
Phase: PHASE2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new infusion drug tame advanced solid tumors?
Disease control CompletedThis early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…
Phase: PHASE1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A machine that keeps donor livers alive outside the body — could it transform transplantation?
Disease control CompletedThis trial tests whether a device called VitaSmart, which pumps cold, oxygenated preservation fluid through a donor liver before transplant, can reduce early organ dysfunction and improve survival compared with the usual method of simply storing the liver on ice. About 228 adults…
Phase: NA • Sponsor: Bridge to Life Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a three-drug cocktail shrink advanced bile-duct tumors?
Disease control CompletedThis phase 2 trial is testing whether combining bevacizumab (a blood-vessel growth blocker) with nab-paclitaxel and an oral chemotherapy called S-1 can shrink tumors in people with advanced biliary tract adenocarcinoma that has worsened after initial treatment. About 32 participa…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Drug combo before and after surgery could boost liver cancer outcomes
Disease control CompletedThis study investigates whether combining two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before and after surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination before surger…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug SHR-7367 takes first step against advanced cancers
Disease control CompletedThis early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could conscious sedation replace general anesthesia for gallbladder drainage?
Disease control CompletedThis study tests whether endoscopic ultrasound-guided gallbladder drainage can be safely performed using conscious sedation given by the endoscopist, instead of deep sedation or general anesthesia. The trial enrolls elderly, high-risk patients with acute cholecystitis who are not…
Sponsor: Azienda Unita Sanitaria Locale di Piacenza • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThis early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Virus hunts liver tumors before chemo strikes
Disease control CompletedThis study tests a cancer-killing virus called JX-594 (Pexa-Vec) in people with advanced liver cancer that cannot be removed by surgery. Participants receive the virus through an IV and then directly into liver tumors, followed by the standard drug sorafenib. The goal is to see i…
Phase: PHASE2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Immunotherapy combo aims to outperform standard care in advanced liver cancer
Disease control CompletedThis phase 3 trial compares a combination of two drugs—toripalimab (an immunotherapy) and bevacizumab (an anti-angiogenic agent)—against the standard drug sorafenib as the first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolls a…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo takes on advanced cancers in first human trial
Disease control CompletedThis early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…
Phase: PHASE1, PHASE2 • Sponsor: Anaveon AG • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New radiation technique aims to protect memory in lung cancer patients
Disease control CompletedThis study tested whether avoiding the hippocampus during whole-brain radiation could reduce memory side effects in people with small cell lung cancer. Over 400 patients received either standard whole-brain radiation or a version that spares the hippocampus. The goal was to see i…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Experimental drug combo aims to shrink inoperable liver tumors
Disease control CompletedThis phase II trial is testing whether a new biologic drug called PM8002, when combined with standard chemotherapy (FOLFOX), can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls about 35 adults with inoperable hepatocellular …
Phase: PHASE2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Smart sugar sensors may improve recovery from complex pancreatic surgery
Disease control CompletedThis study tests whether using a real-time continuous glucose monitor (RT-CGM) during pancreaticoduodenectomy (a complex surgery) helps keep patients' blood sugar in a safe range and improves recovery. About 246 adults scheduled for this surgery will be randomly assigned to stand…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Robotic surgery through the mouth could eliminate neck scars in thyroid cancer patients
Disease control CompletedThis trial compares a new robotic surgery that removes the thyroid through the mouth (transoral vestibular approach) to the standard open surgery with a neck incision. The study includes 430 adults aged 18–65 with papillary thyroid cancer. The goal is to see if the robotic method…
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy combo aims to shrink advanced liver tumors
Disease control CompletedThis phase 2 trial investigates whether combining toripalimab (an immunotherapy) with bevacizumab (a drug that cuts off tumor blood supply) can safely shrink advanced liver cancer when used as the first treatment. About 50 to 60 adults with intermediate or late-stage liver cancer…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy combo targets rare, aggressive lung cancer
Disease control CompletedThis trial investigates whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (carboplatin and etoposide) helps people with a rare and aggressive lung cancer called large cell neuroendocrine carcinoma (LCNEC). The study enrolls adults with advanc…
Phase: PHASE1 • Sponsor: Oncology Center of Biochemical Education And Research • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Personalized vaccine plus immunotherapy shows promise for tough lung cancer
Disease control CompletedThis study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab…
Phase: PHASE1, PHASE2 • Sponsor: Instituto Oncológico Dr Rosell • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Engineered virus takes on liver cancer when standard treatment fails
Disease control CompletedThis trial investigates whether JX-594 (Pexa-Vec), a virus modified to attack cancer cells and boost the immune system, combined with best supportive care, can help people with advanced liver cancer live longer. The study enrolls adults whose liver cancer has progressed or who co…
Phase: PHASE2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Double immunotherapy plus liver blockade targets eye cancer that spreads
Disease control CompletedThis trial investigates whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a procedure called immunoembolization can help people whose uveal melanoma has spread to the liver. The drugs help the immune system attack cancer cells, while immunoembolization cut…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo aims to shrink tough head and neck tumors
Disease control CompletedThis study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Two-Drug combo aims to stall rare gut tumors
Disease control CompletedThis trial tests whether combining two drugs—RAD001 (everolimus) and octreotide depot—can slow tumor growth in people with advanced low-grade neuroendocrine cancer (carcinoid or islet cell tumors) that has spread or cannot be removed surgically. Participants take RAD001 daily by …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could drug holidays improve thyroid cancer treatment?
Disease control CompletedThis study compares two ways of taking the drug pazopanib for people with advanced differentiated thyroid cancer that no longer responds to radioactive iodine. One group takes pazopanib continuously, while the other takes planned breaks and restarts the drug only if the cancer pr…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Double-Barreled chemo attack on bile duct cancer shows promise
Disease control CompletedThis study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
Disease control CompletedThis study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control CompletedThis study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Community strategies show promise in curbing hazardous drinking
Disease control CompletedThis study tests a 5-week community-based program that teaches protective behavioral strategies to reduce alcohol use in men aged 35–44 with hazardous drinking habits in rural Vietnam. Participants learn to set safe drinking limits, choose nonalcoholic drinks, and plan ahead, wit…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Phase: PHASE1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
Disease control CompletedThis clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThis trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…
Phase: PHASE1, PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo shows promise for tough lung cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and sh…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer trial tests two new combo therapies against tough disease
Disease control CompletedThis phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control CompletedThis study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
One-Patient trial tests keytruda for rare ovarian cancer
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Beca…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Fish oil supplement tested for muscle loss in liver cancer patients
Disease control CompletedThis completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…
Phase: NA • Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of three drugs—camrelizumab, apatinib, and chemotherapy (gemcitabine plus cisplatin)—in 49 people with advanced biliary tract cancer that could not be removed by surgery. The goal was to see if the combo is safe and how well it shrinks tumors. Resu…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Modified virus injected into tumors shows promise for liver cancer
Disease control CompletedThis phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…
Phase: PHASE2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
Disease control CompletedThis small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…
Phase: PHASE2 • Sponsor: Howard S Hochster • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo tested for tough lung cancer – modest hopes
Disease control CompletedThis study looked at adding sunitinib malate (a drug that blocks tumor blood flow) to standard chemotherapy for people with extensive-stage small cell lung cancer. The trial involved 156 participants and aimed to find the best dose and see if maintenance sunitinib after chemo cou…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo approach before surgery may improve outcomes for massive liver tumors
Disease control CompletedThis study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising drug cocktail targets Hard-to-Treat liver cancer
Disease control CompletedThis study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase: PHASE3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental vaccine targets Hard-to-Treat cancers in first human test
Disease control CompletedThis early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Heat zaps tiny thyroid tumors, no scalpel needed
Disease control CompletedThis study tested a procedure called radiofrequency ablation, which uses heat to destroy small thyroid cancers. 27 adults with low-risk papillary thyroid microcarcinoma who did not want surgery or active monitoring took part. The goal was to see if the treatment could eliminate t…
Sponsor: Premier G Med Cardio Kft • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…
Phase: PHASE2 • Sponsor: Tae Won Kim • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise for tough pituitary tumors
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo for liver cancer passes safety check in 1,200 patients
Disease control CompletedThis study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Shorter radiation may be as effective for lung cancer
Disease control CompletedThis study tested whether a shorter course of radiation (hypofractionated) given with chemotherapy works as well as the standard longer radiation course for people with limited-stage small cell lung cancer. 860 adults aged 18-70 with early-stage disease took part. The main goal w…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail may make inoperable liver cancer removable
Disease control CompletedThis study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immunotherapy cocktail before surgery shows promise against tough cancers
Disease control CompletedThis study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus injection targets liver tumors in early trial
Disease control CompletedThis early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…
Phase: PHASE1 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New radioactive compound shows promise in targeting Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast cancer, sarcoma, or thyroid cancer) that had spread and no longer responded to standard treatments. The main goals were to see if the drug is safe and how it…
Phase: EARLY_PHASE1 • Sponsor: Lanzhou University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise in controlling advanced liver cancer
Disease control CompletedThis study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Radioactive beads show promise for liver tumors in french registry
Disease control CompletedThis completed registry tracked 332 liver cancer patients in France who received SIR-Spheres, tiny radioactive beads injected into the liver's blood supply to target tumors. The goal was to see how this treatment is used in everyday practice and to monitor safety and survival. Re…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for Chemo-Resistant lung cancers?
Disease control CompletedThis study tested a pill called abemaciclib in 14 people with certain lung cancers (like small cell lung cancer) that stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors and to check its safety. While the drug targets a specific protein to slow…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a triple therapy beat back tough liver cancer?
Disease control CompletedThis completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase: PHASE1, PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Yeast vaccine shows promise in stopping Cancer's return
Disease control CompletedThis early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …
Phase: PHASE1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug shows promise in early liver cancer trial
Disease control CompletedThis early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…
Phase: PHASE1 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Zapping adrenal tumors could lower blood pressure without surgery
Disease control CompletedThis study tested a procedure called radiofrequency ablation, which uses heat to destroy a small adrenal gland tumor that causes high blood pressure. Researchers wanted to see if it could safely lower blood pressure in 31 patients with primary aldosteronism. The goal was to reduc…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Radiation may buy time for liver cancer patients before stronger meds needed
Disease control CompletedThis study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Exergaming and mediterranean diet tested for thyroid cancer recovery
Disease control CompletedThis study looked at whether playing active video games (exergaming) and following a Mediterranean diet could help people who had their thyroid removed due to cancer. 80 adults were split into four groups: one did exergaming, one followed the diet, one did both, and one had no ex…
Phase: NA • Sponsor: Nabil Mahmoud Ismail Abdel-Aal • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug combo shows promise in slowing rare gut tumors
Disease control CompletedThis study tested whether adding the drug axitinib to standard sandostatin LAR therapy could slow tumor growth in 256 people with advanced neuroendocrine tumors (G1-G2) that started outside the pancreas. Participants received either the combination or sandostatin plus a placebo. …
Phase: PHASE2, PHASE3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Keytruda may keep liver cancer at bay after surgery
Disease control CompletedThis large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radiation zaps liver tumors in patients too sick for surgery
Disease control CompletedThis pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThis study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for intermediate liver cancer
Disease control CompletedThis study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Liver cancer patients get new hope: study tests two drug cocktails after first treatment fails
Disease control CompletedThis study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for cancer patients when immunotherapy fails?
Disease control CompletedThis early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…
Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Immunotherapy drug shows promise in bile duct cancer trial
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…
Phase: PHASE1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Double antenna ablation shows promise for small liver tumors
Disease control CompletedThis study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope: hepatitis c drugs after liver cancer treatment
Disease control CompletedThis study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…
Phase: PHASE3 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New triple therapy shows promise for aggressive lung cancer
Disease control CompletedThis study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer. 34 adults took part. The goal was to see if the combo helps delay cancer growth o…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New chemo cocktail shows promise against tough bile duct cancer
Disease control CompletedThis study tested two different chemotherapy drug combinations in 92 people with advanced bile duct or gallbladder cancer that could not be removed by surgery. The goal was to see which combination better kept the cancer from growing for at least 6 months. Participants received e…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
HIV patients with liver failure get new drug combo tested in transplant study
Disease control CompletedThis study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for bile duct cancer: triple therapy shows promise after chemo fails
Disease control CompletedThis Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemo…
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Radioactive oil injection may keep liver cancer at bay
Disease control CompletedThis phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Surgeons test wrapping trick to prevent pancreatic leaks after whipple
Disease control CompletedThis study tested a new way to reconnect the pancreas to the intestine during Whipple surgery for certain cancers. The new method uses a stent and wraps the connection with omentum (fatty tissue) to try to prevent leaks. 48 patients were split into two groups to compare the new t…
Phase: NA • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug BAT8010 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis phase II trial tested whether giving the immunotherapy drug tislelizumab, alone or combined with the targeted therapy lenvatinib, before surgery could help shrink liver tumors in 36 patients with resectable hepatocellular carcinoma. The main goal was to see if at least half …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New radiation approach aims to tame pituitary tumors with fewer side effects
Disease control CompletedThis study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tu…
Phase: NA • Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Precision radiation zaps untreatable liver tumors in tiny pilot study
Disease control CompletedThis study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor …
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy-Ablation combo shows promise in early liver cancer trial
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy shows promise for hard-to-treat thyroid cancer
Disease control CompletedThis study tested whether combining targeted drugs (trametinib and dabrafenib) with radioactive iodine can help shrink or control advanced thyroid cancer that has stopped responding to standard radioactive iodine treatment. The trial enrolled 40 adults with specific gene mutation…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy shows promise in liver cancer battle
Disease control CompletedThis study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo tackles tough liver cancer in tiny trial
Disease control CompletedThis small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very…
Phase: PHASE1 • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for lymphoma patients after CAR T-Cell failure
Disease control CompletedThis study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental combo for bile duct cancer shows promise in tiny trial
Disease control CompletedThis phase 2 study tested a combination of two drugs, durvalumab and SNDX-6352, in 5 people with advanced bile duct cancer that had not spread beyond the liver. Participants first received standard chemo or radiation therapy directly into the liver, then the drug combination. The…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
High-dose radiation beams target liver tumors with precision
Disease control CompletedThis study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-1…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of the targeted drug regorafenib with chemotherapy (mGEMOX) in 66 people with advanced bile duct cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. This is not a cure, but aims to cont…
Phase: PHASE1, PHASE2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for liver cancer: triple therapy shows promise
Disease control CompletedThis study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…
Phase: PHASE2, PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Lenvatinib under the microscope: safety check for tough thyroid cancers
Disease control CompletedThis study looked at the safety of the drug lenvatinib in 50 people with advanced thyroid cancer that had stopped responding to radioactive iodine treatment. Researchers tracked side effects and how often patients needed to lower their dose. They also checked whether tumors shran…
Phase: PHASE4 • Sponsor: Eisai Pharmaceuticals India Pvt. Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New bispecific antibody shows promise for unresectable liver cancer
Disease control CompletedThis phase II trial tested a drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. AK112 is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth. The study measured safety and how well the drug shrank …
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Targeted drug shows promise for rare bile duct cancer
Disease control CompletedThis study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). Participants had already tried chemotherapy without success. The goal was to see if the drug could shrink tumors. Results help determ…
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Real-World check: does zepzelca help advanced lung cancer patients?
Disease control CompletedThis study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, sur…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver (HAIC) in 30 adults with advanced liver cancer that had spread into the main portal vein. The goal was to see if the combination could improve one-year survival.…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Keyhole vs. open surgery: which is safer for pancreatic cancer?
Disease control CompletedThis study compared two surgical methods—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called periampullary adenocarcinoma. Forty patients were enrolled to see which approach led to fewer complications like pancreatic fistula. The goal was t…
Phase: NA • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control CompletedThis phase II trial tested the drug infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The study measured how many patients' tumors shrank or stabili…
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill targets genetic flaw in tough cancers
Disease control CompletedThis early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo shows promise for rare thymic cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and lenvatinib, in 43 people with advanced thymic carcinoma or a related thymoma that had worsened after standard chemotherapy. The goal was to see if the combination could stop or slow cancer growth. Participants receiv…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets brain tumors with IDH mutations
Disease control CompletedThis early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a tropical fruit rind help Pre-Diabetic obesity? new study investigates
Disease control CompletedThis study tested whether Garcinia cambogia rind powder, a dietary supplement, can improve weight, blood sugar, and cholesterol in 90 pre-diabetic obese adults aged 30-60. Participants took the powder daily for 12 weeks. The goal was to see if it helps control metabolic problems …
Phase: NA • Sponsor: University of Lahore • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise for tough liver cancer
Disease control CompletedThis study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that did not respond to or could not tolerate prior treatment. The goal was to see if the combination could shrink tumors and cont…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo aims to stop liver cancer recurrence in High-Risk patients
Disease control CompletedThis early-stage trial tested whether combining donafinib (a targeted therapy) with an anti-PD-1 antibody (an immunotherapy) can safely prevent liver cancer from coming back after surgery. It involved 30 patients with high-risk features like microvascular invasion or multiple tum…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Immunotherapy after Chemo-Radiation shows promise for lung cancer
Disease control CompletedThis study looked at 45 patients with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. The goal was to see how long patients went without their cancer getting worse. Because this was a small, single-center review, …
Sponsor: Anhui Shi, MD • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental CAR-T therapy takes on tough lymphomas
Disease control CompletedThis early-phase trial tested a new treatment called BZ019, made from a patient's own immune cells modified to attack cancer. It involved 12 adults with aggressive B-cell lymphomas that had not responded to standard therapy. The main goals were to check safety and see if the trea…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (nivolumab) and chemotherapy drugs (nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin) in 34 people with advanced biliary tract cancer that had worsened after initial treatment. The goal was to see if the combo could…
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New technique shields healthy liver during cancer radiation
Disease control CompletedThis study tested a method to protect healthy liver tissue during Yttrium-90 radioembolization, a radiation treatment for liver cancer. Doctors injected short-acting gelatin particles into arteries supplying non-cancerous liver areas to temporarily block blood flow. The goal was …
Phase: NA • Sponsor: Next Biomedical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a statin boost liver cancer survival?
Disease control CompletedThis study tested whether adding the cholesterol-lowering drug pravastatin to the standard cancer drug sorafenib helps people with advanced liver cancer live longer. It included 474 adults with Child-Pugh A cirrhosis whose cancer could not be cured. The main goal was to see if th…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New liver cancer treatment shows promise in early trial
Disease control CompletedThis early-stage study tested a chemotherapy drug called idarubicin mixed with a contrast oil (lipiodol) injected directly into the liver artery for people with liver cancer that cannot be removed by surgery. The 15 participants all had cirrhosis. The goal was to find a safe dose…
Phase: PHASE1 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy shows promise for kids with rare lymphoma
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy drugs (etoposide, doxorubicin, vincristine, cyclophosphamide) plus the targeted drug rituximab in 47 children and teens with primary mediastinal large B-cell lymphoma. The goal was to see how well the regimen prevented the c…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New device combo for liver chemotherapy shows promise in small trial
Disease control CompletedThis study tested whether a Medtronic pump and Codman catheter can safely deliver chemotherapy directly to the liver in 35 people with colorectal cancer or bile duct cancer that spread to the liver. The main goal was to check safety, including liver side effects and need for sten…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New stem cell transplant shows promise for kids with tough cancers
Disease control CompletedThis study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Phase: PHASE1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Radioactive microspheres show promise in early liver cancer trial
Disease control CompletedThis completed Phase 1 trial tested a new injection called NRT6003, which contains tiny radioactive beads (yttrium-90), in 40 people with liver cancer that could not be removed by surgery. The goal was to see if the treatment is safe and whether it can shrink tumors in the liver.…
Phase: PHASE1 • Sponsor: Chengdu New Radiomedicine Technology Co. LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
First human trial of BI 765049 combo aims to fight hard-to-treat cancers
Disease control CompletedThis early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental Two-Pronged immune therapy tackles tough lymphoma
Disease control CompletedThis early-phase study tested a new cell therapy called C-CAR039 in 3 adults with B-cell non-Hodgkin's lymphoma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and CD20) on cancer cells. T…
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo shows promise for tough liver and bile duct cancers
Disease control CompletedThis study tested a new combination treatment for people with advanced liver cancer or bile duct cancer. The treatment combines an immunotherapy drug (SHR-1210) with either a targeted therapy (apatinib) or chemotherapy. The goal was to see if the combination is safe and can shrin…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Triple therapy boosts survival in tough liver cancer cases
Disease control CompletedThis study tested whether adding a liver-directed chemotherapy infusion (HAIC) to the usual combination of lenvatinib and an immunotherapy drug (PD-1 inhibitor) helps people with advanced liver cancer that has spread into the main blood vessel of the liver. 244 patients with high…
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New nanoparticle chemo shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…
Phase: PHASE1 • Sponsor: SN BioScience • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New radiation approach may reduce side effects in breast cancer treatment
Disease control CompletedThis study compared two radiation methods for people with early-stage breast cancer: a shorter, more focused radiation (accelerated partial breast irradiation) versus standard whole breast radiation. The goal was to see which causes fewer side effects like skin problems, breast s…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New combo therapy shows promise for tough liver cancer
Disease control CompletedThis study tested a three-drug combination for people with advanced liver cancer that has spread into the portal vein (a major blood vessel). The treatment adds a liver-directed chemotherapy infusion to two standard drugs (lenvatinib and a PD-1 inhibitor). The goal was to see if …
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cocktail shows promise for tough lung cancer
Disease control CompletedThis study tested a combination of three drugs—nivolumab, ipilimumab, and plinabulin—in 39 adults with recurrent small cell lung cancer that had worsened after initial chemotherapy. The goal was to find the safest dose and see if the combo could slow cancer growth. Results from t…
Phase: PHASE1, PHASE2 • Sponsor: Salma Sabbour • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Robotic vs open: which whipple surgery is safer for pancreatic cancer?
Disease control CompletedThis study compared miniinvasive (robotic or laparoscopic) Whipple surgery to the traditional open approach in 320 patients with pancreatic, bile duct, or ampulla of Vater cancers. The goal was to see which method leads to fewer complications like pancreatic leaks, bleeding, or i…
Phase: NA • Sponsor: State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for bile duct cancer? keytruda and lenvima combo tested
Disease control CompletedThis phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and lenvatinib (Lenvima), in 27 people with advanced biliary tract cancer that had worsened after standard treatment. The goal was to see if the combination could shrink tumors. The study is now comple…
Phase: PHASE2 • Sponsor: Shanghai Jiahui International Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail shows promise in preventing bile duct cancer return after surgery
Disease control CompletedThis study tested a combination of three drugs (capecitabine, lenvatinib, and tislelizumab) given after surgery to 65 adults with biliary tract cancer. The goal was to see if this treatment could help keep the cancer from coming back. The results focus on how long patients lived …
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Microwave ablation boosts immunotherapy in advanced liver cancer study
Disease control CompletedThis study looked at 52 adults with advanced liver cancer to see if adding microwave ablation (MWA) to immunotherapy works better than immunotherapy alone. MWA uses heat to destroy tumors and may help the immune system fight cancer more effectively. The researchers measured how l…
Sponsor: The First People's Hospital of Neijiang • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase: PHASE1, PHASE2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail shows promise for tough lung cancer after chemo fails
Disease control CompletedThis study tested a combination of two drugs, anlotinib and penpulimab, in 65 patients with small cell lung cancer whose disease had worsened after initial platinum-based chemotherapy. Anlotinib blocks blood vessel growth to tumors, while penpulimab helps the immune system attack…
Phase: PHASE2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radiation beads aim to shrink liver tumors in neuroendocrine cancer trial
Disease control CompletedThis phase II trial tested a treatment called TheraSphere selective internal radiation therapy (SIRT) in 24 patients with neuroendocrine tumors that had spread to the liver and could not be surgically removed. The treatment involves injecting tiny radioactive beads into the liver…
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Liver cancer remission: is surgery still needed?
Disease control CompletedThis study looked at liver cancer patients whose tumors shrank completely after non-surgical treatments like chemoembolization and immunotherapy. Researchers compared those who then had surgery to remove any remaining tissue versus those who simply watched and waited. The goal wa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Triple drug cocktail shows promise for untreated liver cancer
Disease control CompletedThis study tested whether adding a third drug (relatlimab) to a two-drug combination (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. The 83 participants received either the three-drug combo or the two-dr…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Glue and omental wrap may cut pancreatic surgery risks
Disease control CompletedThis completed Phase 4 trial tested a new surgical technique during Whipple surgery for resectable periampullary tumors. The method uses an omental patch and surgical glue to reinforce the pancreatic connection, aiming to reduce leaks, bleeding, and stomach emptying problems. Thi…
Phase: PHASE4 • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug JAB-8263 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Triple chemo attack shows promise against tough bile duct cancers
Disease control CompletedThis phase III trial tested whether adding nab-paclitaxel to the standard two-drug chemo (gemcitabine and cisplatin) helps people with newly diagnosed, advanced biliary tract cancers live longer. Over 450 patients took part. The goal is to see if the three-drug combo improves ove…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Combination therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received bo…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New 'Smart' cut during ERCP aims to slash complication rates
Disease control CompletedThis study tested a new way to open the bile duct during an ERCP procedure. Instead of the standard pull-type cut, doctors used a special hooked knife (ASD) designed to cut only the circular muscle layer, potentially causing less damage. Over 1,500 patients were randomly assigned…
Phase: NA • Sponsor: Military Medical Clinical Center of the Southern Region, Ukraine • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase: PHASE1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Triple-Drug cocktail shows promise against advanced liver cancer
Disease control CompletedThis study looked at whether adding a mix of three drugs (thalidomide, carmofur, and a traditional Chinese medicine) to a standard procedure called TACE helps people with advanced liver cancer live longer. The study involved 545 patients and compared the combination treatment to …
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Robot surgeons take on pancreatic cancer in major trial
Disease control CompletedThis study compared robotic-assisted pancreatic surgery to the standard open approach for people with pancreatic and related tumors. Researchers wanted to see if robotic surgery could help patients recover faster after the operation. A total of 268 patients took part across multi…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise for rare ovarian cancer in early trial
Disease control CompletedThis phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how m…
Phase: PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cancer drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Genetic test may spare patients from unnecessary thyroid surgery
Diagnosis CompletedThis study evaluates Thyroscan, a genomic test that analyzes genetic material from thyroid nodule samples, to see if it can accurately distinguish benign from malignant nodules. The trial involves 250 adults with suspicious thyroid nodules who are scheduled for surgery or have st…
Sponsor: Rigen Biotech • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New PET scan could spot liver cancer sooner
Diagnosis CompletedThis study tested a special PET/MRI scan that uses a radioactive tracer to find liver cancer cells. The goal was to see if this scan can detect liver cancer earlier and more accurately than standard scans. 52 adults with liver cancer took part, and researchers compared the new sc…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
AI outperforms some doctors in spotting thyroid cancer on ultrasound
Diagnosis CompletedThis study tested an artificial intelligence (AI) system called Vision-LSTM to see if it could accurately diagnose a specific type of thyroid nodule (TI-RADS 4b) from ultrasound images. Researchers used images from 401 patients and compared the AI's performance to that of junior …
Sponsor: Ma Zhe • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can AI help surgeons see thyroid cancer more clearly?
Diagnosis CompletedThis trial is testing whether an AI-assisted ultrasound system can help surgeons plan thyroid cancer surgery. People scheduled for thyroid surgery will receive a standard ultrasound followed by an AI-assisted repeat exam. The AI identifies and scores thyroid nodules, and the stud…
Phase: NA • Sponsor: Fujian Medical University • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Can AI read tumor slides to outsmart childhood cancer?
Diagnosis CompletedThis trial is testing whether an artificial intelligence (AI) model can accurately diagnose and grade several types of solid tumors that affect children, including neuroblastoma, medulloblastoma, Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. The AI is trained on thousands of…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
New screening strategy could speed diagnosis of inherited aldosteronism
Diagnosis CompletedThis study tests a new screening method to tell apart two causes of high blood pressure: a rare genetic condition called Glucocorticoid-Remediable Aldosteronism (GRA) and a more common adrenal tumor. The approach combines an overnight dexamethasone suppression test with detailed …
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New blood test may spot liver cancer sooner in High-Risk patients
Diagnosis CompletedThis study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …
Phase: NA • Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New scan lights up hidden gut tumors
Diagnosis CompletedThis completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accuratel…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New imaging agent could sharpen detection of rare tumors
Diagnosis CompletedThis early-phase study tested a new way to make a radioactive tracer called 68Ga-DOTATOC for PET-CT scans in 20 adults with suspected or known neuroendocrine tumors. The goal was to see if this new method could find tumors more accurately than the current standard scan (OctreoSca…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New scan could spot hidden tumors
Diagnosis CompletedThis early study tested a new radioactive tracer called [18F]3F-PHPG to see if it can help locate neuroendocrine tumors during PET scans. 32 adults with these tumors received the tracer and had two scans. The goal was to check image quality and how the tracer spreads in the body,…
Phase: EARLY_PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
New biopsy technique may spot hidden abdominal cancers without major surgery
Diagnosis CompletedThis study looked at how well a special biopsy method called EUS-FNB can diagnose hard-to-reach tumors in the abdomen, such as those near the bile duct or small intestine. Researchers reviewed data from 131 patients who had this procedure over 10 years. The goal was to see if thi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Which biopsy method best spots bile duct cancer?
Diagnosis CompletedThis study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New ultrasound trick spots liver cancer treatment success days earlier
Diagnosis CompletedThis study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
AI takes on radiologists: can a computer beat the standard for liver cancer diagnosis?
Diagnosis CompletedThis study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Minutes, not days: new rapid test could speed up thyroid cancer detection
Diagnosis CompletedThis study tested a new rapid test that checks for thyroid cancer spread to neck lymph nodes in just minutes, instead of the usual days-long wait. Researchers studied 250 adults with suspected or known thyroid cancer, comparing the quick test to standard lab methods. The goal was…
Sponsor: Soroka University Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New blood markers could revolutionize liver cancer diagnosis
Diagnosis CompletedThis study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…
Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Blow into this tube: a simple breath test might spot liver disease early
Diagnosis CompletedThis study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New blood test could spare bile duct cancer patients unnecessary surgery
Diagnosis CompletedThis study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Quick MRI may outshine ultrasound for liver cancer detection
Diagnosis CompletedThis study tested whether a shorter, contrast-enhanced MRI (called AMRI) is better than standard ultrasound for finding liver cancer early in people with cirrhosis. 79 adults with cirrhosis underwent both scans, and researchers compared how accurately each method detected cancer.…
Phase: PHASE4 • Sponsor: University of California, San Diego • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New blood test may spot liver cancer earlier in hepatitis c patients
Diagnosis CompletedThis study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…
Sponsor: Benha University • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
AI watches dye flow to predict cancer spread in thyroid surgery
Diagnosis CompletedThis study tested whether a computer program (deep learning) can predict if papillary thyroid cancer has spread to lymph nodes beyond the first draining node. During surgery, 131 adults with no signs of lymph node spread received injections of two dyes near the tumor. A camera re…
Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New PET scan could spot liver cancer spread more clearly
Diagnosis CompletedThis phase 2 trial tested whether a special PET scan using a radioactive tracer called 68Ga-PSMA can better detect advanced liver cancer that has spread. The tracer attaches to a protein found on liver cancer cells, making them visible on the scan. The study involved 29 adults wi…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New PET scan shows promise for detecting rare tumors
Diagnosis CompletedThis study tested a new imaging method called [68Ga]Ga-DOTA-TATE PET/CT to see how well it finds neuroendocrine tumors compared to standard scans. It included 71 adults in Japan, both with and without the disease. The goal was to prove the new scan works well for diagnosis in Jap…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
Which biopsy is best for hilar cancer? new study aims to find out
Diagnosis CompletedThis study compares two ways to get tissue samples from a suspected hilar bile duct cancer: one using an endoscope with ultrasound guidance (EUS-FNA/B) and another using a scope to look directly into the bile ducts (ERCP with or without a special camera). Researchers will check w…
Sponsor: Qilu Hospital of Shandong University • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
Blow into this tube: a new breath test could spot liver cancer and COVID-19
Diagnosis CompletedThis study by Mayo Clinic tested whether analyzing chemicals in a person's breath could help diagnose or predict the course of liver disease, liver cancer, and COVID-19. Researchers collected breath samples from 46 participants and looked for unique patterns of volatile organic c…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
Could a simple blood test replace the annoying 24-Hour urine collection for tumor diagnosis?
Diagnosis CompletedThis study looked at 116 people with small-intestine neuroendocrine tumors to see if a blood test or a shorter urine collection could replace the standard 24-hour urine test for diagnosis. The goal was to find a simpler, equally accurate way to measure a key tumor marker called 5…
Phase: NA • Sponsor: CHU de Reims • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Could a simple saliva test replace blood draws for cortisol screening?
Diagnosis CompletedThis study looked at whether a saliva test can accurately measure cortisol levels after a dexamethasone suppression test, compared to the standard blood test. Researchers studied about 100 patients with adrenal incidentalomas (non-cancerous growths on the adrenal gland) and 100 h…
Sponsor: Rigshospitalet, Denmark • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New PET scan tracer could shine a light on hidden pancreatic tumors
Diagnosis CompletedThis study tested a new radioactive tracer called 18F-Exendin-4, used with PET/CT scans, to see if it can better detect insulinoma—a rare tumor in the pancreas that causes dangerously low blood sugar. Twenty participants with confirmed insulinoma received the tracer and underwent…
Sponsor: Sichuan Provincial People's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Can everyday drugs shield the liver from Cirrhosis's worst threats?
Prevention CompletedThis clinical trial investigates whether two existing medications, allopurinol and atorvastatin, can help prevent serious complications in people with stable liver cirrhosis. The study will compare these drugs against a placebo to see if they reduce the number of acute decompensa…
Phase: PHASE2, PHASE3 • Sponsor: Tanta University • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Virtual fitness and nutrition program aims to keep older men on their feet
Prevention CompletedThis pilot study tested a virtual program designed to help older men at high risk for fractures reduce their risk of falls and broken bones. The program included personalized exercise plans delivered through a smartphone app and virtual nutrition counseling. Researchers enrolled …
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Probiotics show promise in stopping autoimmune diseases before they start
Prevention CompletedThis study tested whether giving a daily mix of two types of friendly bacteria (Lactobacilli) to children at genetic risk could prevent or slow down autoimmune diseases like celiac disease, type 1 diabetes, and thyroid problems. The researchers enrolled 202 children who already h…
Phase: NA • Sponsor: Lund University • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
Spinal injection may shield brain from lymphoma spread
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years t…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 18, 2026 03:00 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedThis trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…
Phase: NA • Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Phase: NA • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Which palliative care approach boosts quality of life in advanced lung cancer?
Symptom relief CompletedThis study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can removing the catheter early speed up liver surgery recovery?
Symptom relief CompletedThis trial investigates whether removing a urinary catheter within 6 hours after laparoscopic liver surgery, as part of an enhanced recovery program, improves urinary function and reduces complications. About 212 adults aged 18 to 75 with benign or malignant liver tumors schedule…
Phase: NA • Sponsor: Yu Zhang • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Sweet relief? candy and honey may shield salivary glands from radiation damage
Symptom relief CompletedThis trial tests whether sucking lemon candy and using honey mouthwash can reduce salivary gland damage caused by radioiodine therapy for thyroid cancer. About 120 adults who have had their thyroid removed and are about to receive radioiodine will be randomly assigned to the cand…
Phase: NA • Sponsor: Cyprus University of Technology • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Can a sedative calm the Body's stress response during brain tumor surgery?
Symptom relief CompletedThis phase 2 trial tests whether giving the sedative dexmedetomidine during pituitary tumor surgery can dampen the body's stress response and improve early recovery. About 64 adults with non-functioning pituitary adenomas undergoing endoscopic transsphenoidal surgery will be rand…
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Could a smartphone app speed up recovery after thyroid surgery?
Symptom relief CompletedThis study tests whether a mobile app that provides education and support before and after thyroid surgery can improve recovery and quality of life. Participants are adults having their first thyroidectomy who own a smartphone. One group gets standard care, while the other also u…
Phase: NA • Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Ancient Mind-Body practice tested as fatigue fighter for men after cancer
Symptom relief CompletedThis study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Talking therapy shows promise for MG patients with depression in tiny pilot study
Symptom relief CompletedThis study looked at whether having a tendency toward depression affects how well people with thymoma-associated myasthenia gravis (MG) respond to psychological counseling. Nineteen adults who had surgery for thymoma and MG received eight sessions of counseling based on Gestalt t…
Phase: NA • Sponsor: Ming-Hsing Chang • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
No-Drain thyroid surgery shows promise for benign nodules
Symptom relief CompletedThis study looked at whether removing benign thyroid nodules without placing a surgical drain is safe and effective. Eighty adults having thyroid surgery were randomly assigned to either the standard drain or a no-drain, sutureless technique. The goal was to see if the no-drain a…
Phase: NA • Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Simple muscle relaxation technique shows promise for thyroid cancer pain
Symptom relief CompletedThis study tested whether a simple relaxation exercise, called progressive muscle relaxation (PMR), could help reduce pain and improve quality of life in people with thyroid cancer. Thirty-two patients undergoing chemotherapy were randomly assigned to do either PMR plus gentle st…
Phase: NA • Sponsor: University of Faisalabad • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
String-Attached stent may ease bile duct cancer surgery prep
Symptom relief CompletedThis pilot study tested a plastic stent with a retrieval string to drain bile in 40 people with resectable bile duct cancer. The goal was to see if the stent could safely reduce bile buildup before surgery. Researchers measured serious complications and how well the stent worked.
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Laser and Light-Sensitive drug shrink lung tumors in early trial
Symptom relief CompletedThis early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New recovery plan cuts hospital time and pain after thyroid surgery
Symptom relief CompletedThis study tested a special recovery program (ERAS) for people having thyroid surgery. The goal was to see if it could reduce pain, nausea, and time spent in the hospital compared to usual care. 143 adults took part, and the program focused on improving comfort and speeding up re…
Sponsor: Assiut University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New study tests better pain control during brain surgery
Symptom relief CompletedThis study looked at two ways to numb a nerve bundle in the face during pituitary gland surgery. The goal was to see which method reduces the amount of anesthesia needed during the operation. Sixty adults having this type of surgery took part. The results help doctors choose the …
Phase: NA • Sponsor: Donia Hany Saad • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Lung cancer patients breathe easier with simple rehab program
Symptom relief CompletedThis study tested an 8-week supervised program of breathing exercises and light strength training for 30 people with advanced lung cancer (stage IIIB/IV) who were also getting chemotherapy. Those in the rehab group could walk farther, breathe better, and reported less coughing an…
Phase: NA • Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Team nursing approach shows promise for lung cancer patients on immunotherapy
Symptom relief CompletedThis study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …
Phase: NA • Sponsor: Shanxi Province Cancer Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Tiny scope, big difference? study tests Microscope-Assisted thyroid surgery
Symptom relief CompletedThis study compared two types of thyroid surgery: one using a microscope and the standard approach. Researchers looked at blood loss, nerve damage, and low calcium levels after surgery in 74 patients with thyroid cancer or other thyroid conditions. The goal was to see if the micr…
Phase: NA • Sponsor: Shahida Islam Medical Complex • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Mindfulness may ease stress for liver patients
Symptom relief CompletedThis study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…
Sponsor: Methodist Health System • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a single pill ease pain after liver cancer procedure?
Symptom relief CompletedThis study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …
Phase: PHASE4 • Sponsor: Sherief Abd-Elsalam • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Can acupuncture and ice chips beat chemo nerve damage?
Symptom relief CompletedThis phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Tailored meals boost recovery after liver cancer surgery
Symptom relief CompletedThis study tested whether a personalized diet plan helps liver cancer patients eat more and recover faster after surgery. 139 patients who had part of their liver removed were split into two groups: one got standard care, the other got a custom meal plan with extra protein drinks…
Phase: NA • Sponsor: Anhui Provincial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could a common numbing drug cut opioid use after liver surgery?
Symptom relief CompletedThis study tested whether giving lidocaine through a vein during and after liver surgery can reduce pain and the need for strong painkillers like opioids. 124 adults having minor liver surgery were randomly assigned to receive either lidocaine or a placebo (salt water). Researche…
Phase: PHASE2, PHASE3 • Sponsor: Lund University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Shea butter and niacinamide cream may ease itching for immunotherapy patients
Symptom relief CompletedThis study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…
Phase: NA • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Numbing the nose vs. the face: which controls surgery blood pressure better?
Symptom relief CompletedThis study tested two methods to keep blood pressure stable and reduce pain during pituitary tumor surgery. Sixty adults received either a numbing injection near the cheekbone or numbing medicine placed inside the nose. The goal was to see which approach better controls blood pre…
Phase: PHASE3 • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Scientists uncover genetic secrets behind rare hormone disorders
Knowledge-focused CompletedThis study looked at nearly 1,400 people with rare conditions like PPNAD, Carney Complex, and Peutz-Jeghers syndrome. The goal was to find the genetic causes and link them to specific symptoms. Researchers used clinical exams and genetic testing to better understand how these dis…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Massive Real-World study tracks Atezolizumab's performance in routine cancer care
Knowledge-focused CompletedThis study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden thyroid cancers: how common are they in patients with thyroiditis?
Knowledge-focused CompletedThis completed study from Minia University looked at 200 patients with autoimmune thyroiditis (an inflamed thyroid) who had thyroid surgery. The goal was to see how often thyroid cancer is found by accident when examining the removed tissue. Researchers checked for cancer in pati…
Phase: NA • Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Skipping thyroid ultrasound after PET may be safe, study suggests
Knowledge-focused CompletedThis study examines whether patients who have a thyroid nodule found on a PET scan can safely skip a follow-up ultrasound without affecting their survival. Researchers will compare death rates over 7 years between those who had an ultrasound within 3 months and those who did not.…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Your DNA may decide how well exercise and diet work for weight loss
Knowledge-focused CompletedThis study is testing whether a specific gene variant (MC4R rs17782313) and metabolic health status influence how men with obesity respond to a 12-week exercise and diet program. Forty men aged 18 to 59 with obesity will be classified as having metabolically healthy or unhealthy …
Phase: NA • Sponsor: Harbin Sport University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Protein shake vs. gut trouble: can whey help athletes digest fructose after heat stress?
Knowledge-focused CompletedThis pilot study tests whether a multi-ingredient whey supplement can reduce fructose malabsorption in healthy adults after hiking under heat stress. Eight participants will consume fructose and have their breath hydrogen measured as a marker of malabsorption, both before and aft…
Phase: NA • Sponsor: Arizona State University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can standard cancer treatment wake up the immune system? a study investigates.
Knowledge-focused CompletedThis study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a tumor-zapping procedure also wake up the immune system?
Knowledge-focused CompletedThis study looks at how two heat-based procedures — radiofrequency ablation and microwave ablation — affect the immune system in people with small liver cancers. Researchers will take blood samples and tissue biopsies before and after treatment to track changes in immune cells. T…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Could your DNA predict thyroid cancer after radiation?
Knowledge-focused CompletedThis study investigates whether certain DNA variants make people more likely to develop thyroid cancer after receiving radiation therapy as a child. Researchers will compare the genetic profiles of about 30 people who developed thyroid cancer and 30 who did not, all of whom were …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Ultrasound inside the body reveals how tumors block the bile duct
Knowledge-focused CompletedThis study uses endoscopic ultrasound—a tiny ultrasound probe on a flexible tube passed through the mouth—to measure the size of the common bile duct in people with jaundice caused by pancreatic or bile duct tumors. Researchers aim to better understand how these tumors compress t…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence could help guide liver cancer treatment after surgery
Knowledge-focused CompletedThis study developed an artificial intelligence model that analyzes MRI scans and pathology images to predict the risk of liver cancer returning after surgery. Researchers used data from over 500 patients who had their liver cancer surgically removed. The goal is to help doctors …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New risk score aims to predict which pancreatic tumors will return after surgery
Knowledge-focused CompletedThis study aims to create a simple risk score to identify patients with pancreatic neuroendocrine tumors (PanNETs) who are at high risk of their cancer returning after surgery. Current methods are not very good at predicting individual risk. Researchers will analyze data from ove…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Scientists mine 1,100 patient records to spot thyroid cancer return risks
Knowledge-focused CompletedThis study examines medical records from over 1,100 adults who had papillary thyroid cancer and were declared cancer-free after initial treatment. Researchers want to identify which patient characteristics—such as age, tumor size, or cancer spread—are linked to a higher chance of…
Sponsor: University of Roma La Sapienza • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
AI model may personalize liver cancer care after surgery
Knowledge-focused CompletedThis study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Could your surroundings trigger a hidden genetic risk?
Knowledge-focused CompletedThis study investigates whether environmental and occupational exposures influence the risk of developing tumors in people who carry an SDHx gene mutation. Researchers will compare two groups of mutation carriers: those who have had a tumor and those who have not. The goal is to …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could a smartphone replace clinic visits for rare tumor survivors?
Knowledge-focused CompletedThis study tests whether a remote monitoring program can reliably track the health of people who have had surgery for pheochromocytoma or paraganglioma (PPGL), rare adrenal tumors. Participants use an internet platform to report their data, which is compared to information collec…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Blood scores may identify low-risk patients after hepatitis c cure, reducing need for lifelong cancer scans
Knowledge-focused CompletedThis study looks at whether simple, non-invasive blood test scores can predict the risk of developing liver cancer in people with advanced liver disease who have been cured of hepatitis C. Researchers analyzed data from 571 adults treated at a single hospital over ten years. The …
Sponsor: Siriraj Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
Knowledge-focused CompletedThis study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Radiation safety study aims to personalize thyroid cancer treatment
Knowledge-focused CompletedThis study collects standard-of-care images from people with differentiated thyroid cancer who are treated with radioactive iodine (Iodine-131). The goal is to better understand how much radiation reaches healthy organs and what dose is needed to destroy thyroid tissue. By gather…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Real-Time tissue test may help surgeons avoid unnecessary neck dissections in thyroid cancer
Knowledge-focused CompletedThis pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…
Sponsor: Eleonora Lori, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New camera could make cancer treatment safer by better tracking radiation
Knowledge-focused CompletedThis study tested whether a new type of camera (VERITON-CT) can accurately measure radiation doses in patients receiving Lutathera, a treatment for certain cancers. Fifteen adults were scanned with both the new camera and a standard camera at different times after treatment. The …
Phase: NA • Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lab study tests antibody that could unlock immune attack on liver cancer
Knowledge-focused CompletedThis completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Study aims to cut hospital time after liver surgery by looking beyond medicine
Knowledge-focused CompletedThis completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New imaging trick could tame radioactive cancer therapy
Knowledge-focused CompletedThis completed Phase 1 study tested whether a PET scan using 64Cu-DOTATATE (Detectnet) can help doctors plan safer doses of Lutathera therapy for people with neuroendocrine tumors. Four participants received both standard Lutathera treatment and extra PET/CT and SPECT/CT scans to…
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists explore GLUT1 protein as a diagnostic clue for rare lung tumors
Knowledge-focused CompletedThis study tested whether a protein called GLUT1 could help doctors better classify lung neuroendocrine tumors. Researchers analyzed tumor samples from 36 patients to see if GLUT1 staining patterns matched tumor type. The goal was to find a more reliable diagnostic tool than curr…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
German study reveals Real-World use of PRRT for neuroendocrine tumors
Knowledge-focused CompletedThis study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe Gut-Liver link in alcohol and fatty liver cancers
Knowledge-focused CompletedThis study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Zambia study tracks hepatitis b outcomes in hundreds of patients
Knowledge-focused CompletedThis study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Could a simple calculation replace a complex testosterone lab test?
Knowledge-focused CompletedThis study compared two methods for measuring bioavailable testosterone in the blood: the standard lab test (radioimmunoassay) and a mathematical calculation. Researchers included 270 men and women aged 18 to 90. The goal was to see if the calculation matches the lab test closely…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
HIV Patients' thyroid health under the microscope
Knowledge-focused CompletedThis study looked at how often thyroid problems (specifically an underactive thyroid) occur in people with HIV. Researchers reviewed medical records of 154 HIV-positive adults who were treated at a French hospital between 2001 and 2012. The goal was to get a clearer picture of th…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study reveals how brain scans predict surgery outcomes for pituitary tumors
Knowledge-focused CompletedThis study looked at 49 people with masses in the sellar region of the brain (near the pituitary gland). Researchers compared MRI scans before surgery with the final diagnosis after surgery to see how well imaging predicts the type of tumor. The goal was to improve diagnosis and …
Sponsor: Arab Board of Neurosurgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Small study tests best way to mix chemo for liver tumors
Knowledge-focused CompletedThis study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…
Phase: PHASE4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to fix lack of diversity in cancer trials
Knowledge-focused CompletedThis completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests and surveys may predict cancer treatment success
Knowledge-focused CompletedThis study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Thousands tracked in Largest-Ever liver cancer bead therapy registry
Knowledge-focused CompletedThis registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Brain radiation may erase personal memories, study warns
Knowledge-focused CompletedThis study looks at how radiation therapy for brain tumors like meningioma or pituitary adenoma might affect autobiographical memory—the memories of your life events. Researchers will ask 17 patients to complete memory tests one and two years after treatment. The goal is to see i…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New ultrasound technique aims to better measure liver health
Knowledge-focused CompletedThis study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Standing ultrasound spots hidden liver tumors better than lying down
Knowledge-focused CompletedThis study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Anesthesia may alter gut bugs after liver surgery
Knowledge-focused CompletedThis study looked at how two different anesthesia methods (propofol vs. desflurane) affect gut bacteria and body chemistry in 60 adults undergoing liver tumor removal. Researchers measured changes in gut microbes and blood metabolites to see if anesthesia choice influences recove…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Sharper scans may make cancer radiation more precise
Knowledge-focused CompletedThis study tested a new cone-beam CT scanner that takes clearer pictures during radiation therapy for lung, liver, and breast cancers. 31 people participated to see if the new scanner reduces image blurring and improves accuracy. The goal is to help doctors target tumors more pre…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Cancer surgery recovery: quality of life under the microscope
Knowledge-focused CompletedThis study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…
Sponsor: University Hospital, Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Hepatitis & liver cancer risk explored in immigrant communities
Knowledge-focused CompletedThis study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Ultrasound vs. MRI: which is better for catching liver cancer early?
Knowledge-focused CompletedThis study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…
Sponsor: JOON-IL CHOI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver scan may predict deadly failure after big operations
Knowledge-focused CompletedThis study tested whether a special liver scan (hepatobiliary scintigraphy) can predict liver failure in 326 patients undergoing major liver surgery. The scan measures how well the remaining liver works, which may be more useful than just measuring its size. If accurate, it could…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Thyroid cancer Drug's side effect on body mass measured in small study
Knowledge-focused CompletedThis completed study from the University of Pisa looked at how the thyroid cancer drug selpercatinib affects body composition. Fifteen adults on the drug had their lean mass and energy expenditure measured. The goal was simply to observe and gather data, not to test a new treatme…
Sponsor: University of Pisa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New study tracks hidden heart and bone risks in Cushing's disease
Knowledge-focused CompletedThis study followed 80 people with newly diagnosed Cushing's disease for three years to see how the disease affects the heart, bones, metabolism, and quality of life. Researchers used blood tests, heart scans, bone density tests, and questionnaires to track complications before a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists peer into liver cancer cells to unlock secrets
Knowledge-focused CompletedThis study looked at liver cancer cells from 30 patients to understand how they differ from healthy cells. Researchers isolated these cells to create 3D lab models called organoids. The goal was to learn more about the behavior and genetics of liver cancer, not to test a new trea…
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Eye scan may forecast vision after brain surgery
Knowledge-focused CompletedThis study tested whether a type of eye scan called OCT-angiography can predict how well vision will recover after surgery to remove a pituitary tumor. Researchers compared the scan results with standard vision tests in 21 patients. The goal was to see if the scan could serve as …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
AI reads MRI scans to predict liver cancer survival
Knowledge-focused CompletedThis completed study looked at 169 patients with a type of liver cancer called intrahepatic cholangiocarcinoma. Researchers used MRI scans and machine learning to measure scar tissue and a protein linked to tumor growth. The goal was to see if these features could predict how lon…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New model helps surgeons choose best operation for rare liver cancer
Knowledge-focused CompletedThis study tested a computer model that helps surgeons decide the best type of surgery for patients with a rare form of liver cancer that has spread into the bile ducts. The model uses patient scans and medical history to recommend whether to remove part of the bile duct or just …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
CT scan clues may guide better liver cancer care
Knowledge-focused CompletedThis study looked at 324 adults with intermediate-stage liver cancer to see if CT scan features could predict how well they would respond to a combination treatment of targeted therapy and a procedure that blocks the tumor's blood supply. The goal was to find out if certain scan …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Researchers watch how SBRT works for liver and pancreatic tumors
Knowledge-focused CompletedThis study looked at how safe and effective a precise type of radiation therapy (SBRT) is for treating liver tumors, liver metastases, and pancreatic tumors. It involved 65 adult patients who were already scheduled for SBRT. The goal was to monitor and improve the treatment proce…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Doctors create new tool to predict surgery difficulty for rare tumors
Knowledge-focused CompletedThis study created a new imaging-based grading system to help doctors predict how complex and risky surgery will be for patients with rare adrenal and nerve tumors called PPGL. Researchers used 3D scans from 500 patients to develop the system, aiming to improve surgical planning …
Sponsor: Peking University First Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Liver cancer patients: do pre-transplant drugs improve outcomes?
Knowledge-focused CompletedThis study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, c…
Sponsor: Hu Liangshuo • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Rare tumor chemotherapy showdown: platinum vs. Non-Platinum
Knowledge-focused CompletedThis study analyzed data from 168 patients with a rare type of digestive neuroendocrine tumor (well-differentiated grade 3). Researchers compared survival and response rates in patients who received platinum-based chemotherapy versus those who received non-platinum chemotherapy. …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Tiny study tests if DNA can decide how much thyroid to remove
Knowledge-focused CompletedThis pilot study tested whether routine genetic analysis of thyroid cancer samples could help surgeons decide how much of the thyroid to remove. Only 2 patients were enrolled. The goal was to see if a larger trial is possible, not to change treatment yet.
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug interaction study: will antibiotics or antifungals change its effects?
Knowledge-focused CompletedThis study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
AI reveals gender differences in liver cancer spread risk
Knowledge-focused CompletedThis study looked at whether liver cancer spreads differently in men and women. Researchers analyzed data from over 19,000 patients and used computer models to create separate prediction tools for each gender. The goal was to better understand risk factors for cancer spread at th…
Sponsor: Tongji University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
AI scans 3000 liver cancer patients to pick best therapy
Knowledge-focused CompletedThis study analyzed medical images and data from 3000 patients with advanced liver cancer that cannot be removed by surgery. Researchers used an AI technique called radiomics to see if they could identify which patients would respond better to one of two standard treatments: TACE…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
AI analyzes CT scans to find safer radiation levels for liver cancer patients
Knowledge-focused CompletedThis completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future tre…
Sponsor: Cao peiguo • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Waistline may predict surgery time for rare adrenal tumor
Knowledge-focused CompletedThis study looked at whether a patient's abdominal circumference (belly size) is linked to how long surgery takes to remove a pheochromocytoma, a rare adrenal tumor. Researchers reviewed records of 159 adults who had the surgery. The goal was to see if belly size could help docto…
Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Cancer patients happier getting immunotherapy at home?
Knowledge-focused CompletedThis French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New registry aims to map biliary tract cancers for future breakthroughs
Knowledge-focused CompletedThis completed registry study gathered information from 159 people with biliary tract cancers, including gallbladder cancer. The goal was to create a detailed database of patient experiences, treatments, and quality of life to help guide future research. No new drug or treatment …
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Microscope or loupes? study tests better tool for liver transplant bile duct repair
Knowledge-focused CompletedThis study compared two surgical tools—surgical loupes (magnifying glasses) and a microscope—for repairing bile ducts during living donor liver transplants. 52 adults receiving a right-lobe liver graft with a single bile duct opening took part. The goal was to see which tool led …
Phase: NA • Sponsor: Istanbul Medipol University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Virtual reality test reveals hidden memory damage in cured Cushing's patients
Knowledge-focused CompletedThis study looked at whether people who have been cured of Cushing's disease for at least a year still have memory problems. Researchers used a special virtual reality test to check memory, along with standard tests. The goal was to better understand these lasting effects and imp…
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can a simple spit test predict chemo-related deafness in kids?
Knowledge-focused CompletedThis study looked at 119 children who had platinum-based chemotherapy for certain cancers. Researchers wanted to find out if certain genes make some kids more likely to develop hearing loss from the treatment. By analyzing DNA from saliva samples, they hope to identify high-risk …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC